SAN DIEGO, Calif., June 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chains, announced today that in May, its subsidiary Kannaway® achieved its highest monthly revenue in company history for its Japanese division.
According to one of the most recent industry reports, the Japanese CBD market is set to become the second largest CBD market in Asiarising to approximately US$1.9 billion by 2024.
“We are proud of our team in Japan for this achievement. Kannaway has increased sales every month so far this year, setting a new company record every month,” said Medical Marijuana, Inc. CEO Blake Schroeder. “We are confident that the demand for CBD products in Japan will continue to grow, as the Japanese CBD market is currently experiencing an annual growth rate of nearly 100% year-over-year.”
To learn more about Kannaway®, please visit the company online at https://www.kannaway.com/
Kannaway® is a network sales and marketing company specializing in the sale and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, providing unique insight and opportunities for sales professionals who want to become successful leaders in the sale and marketing of botanicals. of hemp.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc.. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Genuine Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and effectiveness.
Medical Marijuana, Inc. is headquartered in San Diego, CA and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To view the Medical Marijuana, Inc. corporate video, Click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any product that violates the United States Controlled Substances Act.
Contact with Investor Relations:
T. (858) 283-4016
#Medical #Marijuana #Subsidiary #Kannaway #Achieves #Largest #Revenue #Month #Company #History #Japan #Division